Galapagos and the University of Bristol entered into a new discovery collaboration in the field of cancer research. Galapagos' service division, BioFocus, will provide lead-optimization services for the University’s research program focusing on destroying cancer cells.
Total contract value for Galapagos exceeds Euro $2M in research fees over two years.
Scientists at ProXara Biotechnology, a spin-out from the University of Bristol, discovered drug-like compounds that prevent PKB activation and make tumor cells commit suicide. BioFocus will apply its Admensa technology to help optimize these drug-like compounds and select a candidate for clinical trials.